Search the Newsreel

Avoiding Lag: Real-Time Signals in (GSK) Movement

This article provides real-time signal analysis for GSK, highlighting weak near-term sentiment but strong long-term projections. It offers three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels …

Xos, Inc. (XOS) director disposes 12,476 shares in 10b5-1 plan

Xos, Inc. director Dietmar Ostermann disposed of a total of 12,476 shares of Common Stock between July 15-17, 2026, under a Rule 10b5-1 trading plan adopted in September 2025. The shares were sold at weighted average prices ranging from $2.11 to $2.34 per share. …

Xos, Inc. (XOS) director reports 3 stock sale transactions under 10b5-1 plan

Xos, Inc. director Michael Paul Richardson reported three dispositions of common stock between July 15-17, 2026, totaling 9,356 shares. These sales were executed under a Rule 10b5-1 trading plan adopted in September 2025, with weighted average sale prices ranging from $2.1487 to $2.3067 per …

Form 4 Xos Inc For: 17 July By Investing.com

This article announces the filing of Form 4 for Xos Inc. for July 17th. It is a brief report from Investing.com, accompanied by various market data and other news headlines.

Xos, Inc. (XOS) director trades 7,500 shares in Rule 10b5-1 plan

Xos, Inc. director Alice Yake disposed of 7,500 shares of common stock across three days, from July 15-17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices between $2.1481 and $2.3042 per share. Following these transactions, Yake …

GSK (GSK) Stock Price, News & Analysis $GSK

GSK (GlaxoSmithKline plc) is a London-headquartered pharmaceutical company focused on prescription medicines, vaccines, and specialty treatments. The company's stock currently has a "Hold" consensus rating from analysts, with a price target of $53.00, approximately 5.5% higher than its current trading price. Recent news indicates …

GSK plc (NYSE: GSK) plans Deloitte re-appointment as external auditor from 2028

GSK plc announced its decision to re-appoint Deloitte LLP as its external auditor starting from the financial year ending December 31, 2028, following a competitive tender process. As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and …

GSK (NYSE: GSK) halts camlipixant cough drug after Phase III data

GSK has decided to halt further development of camlipixant for refractory chronic cough (RCC) after mixed results from its CALM-1 and CALM-2 Phase III trials. While the 50mg dose achieved the primary endpoint of reducing cough frequency in CALM-1, it failed to meet statistical …

Gaxos.ai sells its gaming assets to Game Foundry AI in $1.76M stock deal

Gaxos.ai has sold its gaming assets to Game Foundry AI for $1.76 million in stock. This transaction involves a newly launched AI company acquiring Gaxos.ai's portfolio of games, signaling a strategic shift for both entities in the gaming and AI sectors.

Axos Financial (NYSE:AX) Hits New 1-Year High - Time to Buy?

Axos Financial (NYSE:AX) shares recently hit a new 52-week high, trading up to $102.18, following a previous close of $98.16. Despite insider selling, institutional ownership remains high at 83.79%, and Wall Street analysts generally maintain a "Buy" rating with an average price target of …

Axos Financial Inc stock hits all-time high at 102.11 USD

Axos Financial Inc. (AX) stock hit an all-time high of $102.11, reflecting strong investor confidence and a 12% revenue growth over the last year. Despite being considered overvalued relative to its fair value by InvestingPro, the company has shown consistent profitability and recently reported …

GSK plc (NYSE: GSK) insiders add ADSs through dividend reinvestment

GSK plc reported that several senior leaders and non-executive directors acquired American Depositary Shares (ADS) between July 10 and July 14, 2026. These acquisitions were a result of the automatic reinvestment of cash dividends paid to shareholders on July 9, 2026, with ADS prices …

BOFI5363672 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Axos Financial, Inc. bond BOFI5363672, detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.00%, with the next payment expected on September 1, 2026. The financial instrument is listed under …

GSK (NYSE: GSK) closes $10.6B Nuvalent deal to expand lung cancer pipeline

GSK has completed its $10.6 billion acquisition of Nuvalent, a clinical-stage biopharmaceutical company, significantly expanding its oncology pipeline. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655), which have FDA Breakthrough Therapy and Orphan Drug Designations and are expected to …

Previsão DEXP3 — Preço Alvo para 2027

GLAXO Forecast — Price Target — Prediction for 2027

GXAI Stock Spikes On Volume As Traders Target Volatility

Xos Inc. (XOS) Edges Higher but Resistance Caps Near-Term Gains - Intraday Profile

Earnings call transcript: Xos Inc. delivers record Q1 2026 results

GlaxoSmithKline Pharmaceuticals Discloses DRI Search at Mumbai Office Under Customs Act

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) market cap surged ₹32b last week, public companies who have a lot riding on the company were rewarded

GlaxoSmithKline Pharma Q3 profit up 29 pc at Rs 296 cr

GlaxoSmithKline Q3 net profit surges 29% on higher revenue and EBITDA

Gaxos.ai Inc. Expands with Strategic Moves Amid Market Fluctuations

Earnings Not Telling The Story For GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

GlaxoSmithKline Pharmaceuticals Ltd. Share Price Live Today

Will Weakness in GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Stock Prove Temporary Given Strong Fundamentals?

GlaxoSmithKline India reports higher second-quarter profit on specialty medicine growth

GLAXO Share Price Today - Glaxosmithkline Pharmaceuticals Stock Analysis

Xos, Inc. (NASDAQ:XOS) Analysts Are Pretty Bullish On The Stock After Recent Results

India's GlaxoSmithKline Pharma posts first revenue drop in over two years

BLUE DOT LIST: Relative Strength Line can be your Game-Changing Tool – Solar Industries India, Krishna Institute of Medical Sciences, GlaxoSmithKline Pharmaceuticals, Bharti Airtel, SBFC Finance hitting new high in RS Line

GlaxoSmithKline Pharma shares jump nearly 16 pc after impressive Q3 earnings

GlaxoSmithKline Pharmaceuticals shares hit 20% upper circuit as profit jumps fivefold in Q3FY25

DEXP3 - Dexxos Participações - Resultados, Dividendos, Cotação e Indicadores